iifl-logo

Q-Line Biotech Ltd Directors Report

Add as a Preferred Source on Google
₹411.5
(-8.27%)
Nov 18, 2026|03:59:40 PM

Q-Line Biotech Ltd Share Price directors Report

Dear Members,

Your directors take pleasure in presenting the 16th Annual report on the affairs of the Company together with the Audited standalone and consolidated Statement of Accounts for the financial year ended on 31st March 2026.

1) FINANCIAL PERFORMANCE OF THE COMPANY:

(Figure In Lakh ( )

PARTICULARS STANDALONE CONSOLIDATED
2025-26 2024-25 2025-26 2024-25
Revenue from Operations 34,115.84 31,307.43 34,173.57 31,314.37
Other Income 573.36 882.96 570.34 882.96
Total Revenues 34,689.19 32,190.39 34,743.90 32,197.33
Profit before Financial Expenses, Preliminary expenses, Depreciation and Taxation 17,394.98 14,580.72 17,328.09 14,541.87
Less: Financial expenses 1,887.70 1,491.32 1,941.68 1,491.32
Profit before Depreciation & Taxation 15507.28 13,089.4 15,386.41 13,050.55
Less: Depreciation & amortization expenses 1,077.83 692.93 1,079.06 703.37
Operating Profit before Other expenses, Prior Period Expenses & Taxation 14429.45 12,396.47 14,307.35 12,347.18
Less: Other expenses and Prior Period Expenses 6,909.96 7,116.61 6,953.21 7,176.44
Profit before Exceptional and Extraordinary Items and Taxation 7,519.49 5,279.86 7,354.14 5,170.74
Add: Extraordinary Items- Income/ (Expenses) (97.77) 1,374.51 (99.17) (1,696.97)
Profit before Taxation 7,421.73 6,654.37 7,254.97 3,473.78
Less: Provision for Taxation
Current Tax 1,885.81 1886.03 1,885.81 1,886.03
Short/(excess) provision of earlier year tax (194.78) 61.70 (194.78) 61.70
Deferred Tax 35.82 (33.02) (8.23) (42.18)
Add Profits from Associates - - - 352.88
Profit for the period 5,694.88 4,739.65 5,572.17 1,921.11

2) RESULT OF OPERATIONS AND STATE OF AFFAIRS: (Amount in Lakhs)

The financial year 2025-26 was a year of strong growth and improved financial performance for the company. During the year under review, the Company witnessed a significant increase in its operating scale and overall revenue as compared to the previous financial year.

The standalone revenue of the Company stood atRs. 34,115.84 Lakhs, and the consolidated revenue stood at Rs. 34,173.57Lakhs, as against the previous financial year, where the standalone revenue was Rs. 31,307.43 Lakhs and the consolidated revenue was Rs. 31,314.37 Lakhs.

The Company continues to maintain a stable financial position and remains focused on strengthening its core business operations, improving margins, and exploring growth opportunities in both domestic and international markets.

3) TRANSFER TO RESERVES:

The Company has transferred a sum of Rs. 5,694.88 Lakhs to the Reserve and Surplus Account during the financial year 2025-26 .

4) DIVIDEND:

The Board has not declared any Dividend during the financial year 2025-26 .

5) STATE OF COMPANYS AFFAIRS AND FUTURE OUTLOOK

Q-Line Biotech Limited has been engaged in the diagnostics industry since its incorporation in 2010. The Company is primarily involved in the development, manufacturing and distribution of diagnostic instruments, reagents and consumables. Its product portfolio includes products used in clinical chemistry, haematology, molecular diagnostics, rapid testing and ELISA, catering to healthcare professionals, diagnostic laboratories and institutions across India. The Company maintains a strong focus on product quality and innovation, holds ISO 13485 certification and operates manufacturing facilities in Uttar Pradesh and Delhi, supporting the Government of Indias Make in India initiative.

During the financial year 2025-26, the Company continued to strengthen its business operations, expand its product portfolio and enhance its manufacturing and operational capabilities. As part of these initiatives, the Company commenced operations at its manufacturing facility situated at Plot No. C-42, Industrial Area, Amausi, Tehsil Sarojini Nagar, Lucknow, Uttar Pradesh-226008, which is expected to augment the Companys production capacity and support its future growth requirements.

During the year under review, the Company also undertook various corporate and capitalraising initiatives in preparation for its Initial Public Offering. The authorised share capital of the Company was increased from 4.00 crore to 25.00 crore in August 2025. Further, the Company issued bonus shares and completed a rights issue in September 2025, thereby strengthening its capital base and capital structure.

The Company continued its focus on research and development, including the development and enhancement of molecular diagnostic kits for infectious diseases and automated nucleic acid extraction systems. Supported by its research and development capabilities, the Company aims to broaden its product offerings and address evolving requirements in the healthcare and diagnostics sector.

The Board remains optimistic about the Companys future prospects. Going forward, the Company intends to focus on strengthening its research and development capabilities, expanding its product portfolio, enhancing manufacturing efficiency and widening its market presence. The Company remains committed to providing reliable, affordable and accessible diagnostic solutions while contributing to the growth of the healthcare ecosystem in India.

6) STATUTORY AUDITORS & AUDIT REPORT :

M/s. R K Jagetiya & Co., Chartered Accountants (Firm Registration No. 146264W), were appointed as the Statutory Auditors of the Company by the members at the 15 th Annual General Meeting held on 30 th September 2025, pursuant to the provisions of Sections 139, 142 and other applicable provisions of the Companies Act, 2013 and the rules made thereunder.

M/s. R K Jagetiya & Co. were appointed for a term of five (5) consecutive years, commencing from the conclusion of the 15 th Annual General Meeting until the conclusion of the 20 th Annual General Meeting of the Company, at such remuneration as may be determined by the Board of Directors in consultation with the Auditors.

The Statutory Auditors Report for the financial year 2025-26 does not contain any qualification, reservation, adverse remark or disclaimer. The observations made by the Statutory Auditors in their report, together with the relevant notes to accounts, are self-explanatory and therefore do not call for any further explanation or comments from the Board.

7) DISCLOSURE OF FRAUD REPORTED BY AUDITOR UNDER SUB-SECTION (12) OF SECTION 143:

During the Financial Year 2025-26, no fraud was reported by the auditors under sub-section (12) of Section 143.

8) FINANCIAL STATEMENTS:

The audited Financial Statements of the Company, which form a part of this Annual Report, have been prepared in accordance with the provisions of the Companies Act, 2013, prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014.

9) WEB ADDRESS WHERE ANNUAL RETURN HAS BEEN PLACED

Pursuant to Section 92(3) read with Section 134(3)(a) of the Companies Act, 2013, the Annual Return of the Company for the financial year 2025-26 is available on the Companys website at https://qlinebiotech.com .

10) DETAILS IN RESPECT OF ADEQUACY OF INTERNAL FINANCIAL CONTROLS WITH REFERENCE TO THE FINANCIAL STATEMENTS PURSUANT TO RULE 8 (5) (viii) OF COMPANIES (ACCOUNTS) RULES,2014:

The Company has adequate internal financial controls with reference to the financial statements, commensurate with the size and nature of its operations. During the year under review, the internal financial controls were reviewed by the Internal Auditor and were found to be adequate and effective. The Internal Auditor also observed that appropriate controls are in place to prevent and detect frauds and errors and to ensure accuracy and reliability of financial reporting.

Certain process and accounting-related observations were made during the audit, which have been duly considered by the management. Appropriate corrective measures have been initiated to address such observations and further strengthen the existing internal controls and processes.

11) MATERIAL CHANGES AND COMMITMENT IF ANY AFFECTING THE FINANCIAL POSITION OF THE COMPANY OCCURRED BETWEEN THE END OF THE FINANCIAL YEAR TO WHICH THIS FINANCIAL STATEMENT RELATE AND THE DATE OF THE REPORT:

Subsequent to the close of the financial year ended March 31, 2026, the Company undertook certain significant corporate, capital market and financial developments, including a Pre-IPO Placement, Initial Public Offering (IPO), listing of its equity shares on the SME Platform of the National Stock Exchange of India Limited (NSE Emerge) and change in its credit rating agency.

i) Pre-IPO Placement

Subsequent to the financial year-end, pursuant to the requisite approvals of the Board of Directors and the Members of the Company, the Company completed a Pre-IPO Placement of 8,00,000 equity shares of face value of 10 each at an issue price of 343 per equity share, aggregating to 27.44 crore. The said equity shares were allotted on May 13, 2026.

ii) Initial Public Offering and Listing

Subsequently, the Company completed its Initial Public Offering (IPO), comprising a fresh issue of 62,53,200 equity shares of face value of 10 each at an issue price of 343 per equity share, including a securities premium of 333 per equity share, aggregating to 214.48 crore.

Pursuant to the completion of the IPO, the equity shares of the Company were listed on the SME Platform of the National Stock Exchange of India Limited (NSE Emerge) on May 29, 2026.

Consequent to the listing of its equity shares, the Company became subject to the applicable provisions of the Securities and Exchange Board of India Act, 1992, the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR Regulations), the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and other applicable securities laws, rules, regulations, circulars and directions, from the date of listing, subject to the exemptions and specific provisions applicable to entities listed on the SME Platform.

The Company has accordingly undertaken the necessary measures to establish and strengthen its systems, policies, processes, internal controls and compliance framework to ensure adherence to the applicable statutory and regulatory requirements arising pursuant to the listing of its equity shares.

iii) Change in Credit Rating Agency

Further, subsequent to the financial year-end, the Company changed its credit rating agency from CRISIL Ratings Limited to CARE Ratings Limited. CARE Ratings Limited has assigned a credit rating of CARE A-; Stable to the Company, as against the earlier rating of CRISIL BBB+; Stable, reflecting an improvement in the Companys credit profile.

The aforesaid Pre-IPO Placement, Initial Public Offering, listing of the Companys equity shares and improvement in its credit rating constitute significant events subsequent to the financial year-end. These developments mark important milestones in the Companys growth and capital-raising journey and have contributed to strengthening its capital base and overall financial and credit profile.

iv) Applicability Of SEBI LODR Regulations To SME-Listed Entity

The Company was not listed on any stock exchange during the financial year ended March 31, 2026. Subsequent to the end of the financial year, the equity shares of the Company were listed on the SME Platform of National Stock Exchange of India Limited (NSE Emerge) on May 29, 2026.

Accordingly, from the date of listing, the Company became subject to the applicable provisions of the Securities and Exchange Board of India Act, 1992, the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR Regulations), the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and other applicable securities laws, rules and regulations.

Being an entity listed on the SME Platform, certain corporate governance provisions of the SEBI LODR Regulations are not applicable to the Company pursuant to Regulation 15(2)(b) thereof, subject to the specific provisions applicable to entities listed on the SME Platform.

Not with standing the aforesaid exemptions, the provisions relating to Related Party Transactions under Regulation 23 of the SEBI LODR Regulations are applicable to the Company, as the paid-up equity share capital of the Company as on March 31, 2026 exceeded 10 crore.

The Company has accordingly taken necessary steps to establish and maintain the requisite framework for identification, review, approval, monitoring and disclosure of Related Party Transactions in accordance with the applicable provisions of the Companies Act, 2013, the SEBI LODR Regulations and the Companys Policy on Materiality of Related Party Transactions and on Dealing with Related Party Transactions.

The Company shall continue to comply with all applicable provisions of the SEBI LODR Regulations and other securities laws, rules, regulations, circulars and directions applicable to an entity listed on the SME Platform, including such provisions as may become applicable based on the Companys size, capitalisation or other prescribed thresholds.

12) SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS OR TRIBUNALS IMPACTING THE GOING CONCERN STATUS AND COMPANYS OPERATIONS IN FUTURE:

During the year under review, there has been no such significant and material orders passed by the regulators or courts or tribunals impacting the going concern status and companys operations in future.

13) SUBSIDIARIES/ JOINT VENTURE/ ASSOCIATE COMPANY:

As on March 31, 2026, the Company had the following subsidiaries/Associate/Joint Venture.

A. Q-Line Iris Pvt Ltd: Joint Venture

The company holds a 50% equity stake in Q-Line Iris Pvt Ltd., a joint venture entered with Infer Radiological and Imaging Services Private Limited for providing Radiological and Imaging Labs, screening centers, research establishments, scan centers, and allied services. The Company has not generated any turnover for the Financial Year ending on 31 st March 2026.

B. Q-Line Innovations Pvt Ltd.: Subsidiary

The Company holds a 70% equity stake in Q-Line Innovations Private Limited, a subsidiary established to carry on research and development for new surgical, medical, dental, diagnostic, and scientific equipment, accessories, kits, reagents, and consumables; to develop substitutes for imported products; and to establish and operate testing laboratories and facilities for both own and third-party use. The subsidiary is also engaged in the manufacturing, trading, importing, exporting, packaging, labelling, leasing, and dealing in such products. During the financial year ended 31 st March 2026, Q-Line Innovations Private Limited generated a turnover of 1,59,46,883.10.

14) DETAILS OF DIRECTORS AND KEY MANAGERIAL PERSONNEL (KMP) & CHANGES IN THE BOARD OF DIRECTORS:

a) The composition of the Board of Directors and Key Managerial Personnel (KMP) of the Company as on the date of this Report is as follows:

S No. Name of Directors/KMP Designation DIN/PAN
1 Saurabh Garg Managing Director & Chairman 02891621
2 Ajay Kumar Mahanty Whole-Time Director 07002517
3 Kuldeep Chowdhry Whole-Time Director 06504620
4 Prabhakara Subraya Yethadka Whole-Time Director 06922503
5 Amita Garg Director 02891610
6 Abhay Agrawal Director 07005258
7 Ayush Garg Director 08748016
8 Pravir Kumar Independent Director 00671671
9 Rohit Nandan Independent Director 02195896
10 Jai Prakash Singh Independent Director 10824246
11 Abhishek Mishra Independent Director 08790634
12 Meenal Gupta Chief Financial Officer ABHPG6642E
13 Akhand Pratap Singh Company Secretary CFRPS7649R

b) During the financial year 2025-26, there were various changes in the composition of the Board of Directors and Key Managerial Personnel (KMP) of the Company. The details of the changes during the financial year are as follows:

S. No Name of Director/ KMP Designation Nature of change Date of Change
1 Pushplata Garg Director Resignation 01-05-2025
2 Y.S. Prabhakara Whole Time Director Appointment 08-05-2025
3 Rohit Nandan Independent Director Appointment 08-05-2025
4 Pravir Kumar Independent Director Appointment 08-05-2025
5 Abhishek Mishra Independent Director Appointment 08-05-2025
6 Jai Prakash Singh Independent Director Appointment 01-08-2025
7 Saurabh Garg Managing Director Change in Designation 01-08-2025
8 Ajay Kumar Mahanty Whole Time Director Change in Designation 01-08-2025
9 Kuldeep Chowdhry Whole Time Director Change in Designation 01-08-2025
10 Meenal Gupta Chief Financial Officer Appointment 25-07-2025
11 Akhand Pratap Singh Company Secretary Appointment 25-07-2025

4

«

Further, there have been no significant changes in the composition of the Board of Directors or Key Managerial Personnel of the Company from the end of the financial year,

i.e., 31st March 2026, up to the date of this Report.

15) NUMBER OF MEETING OF THE BOARD & MEMBERS

During the financial year 2025-26, nineteen (19) Board Meetings were held in accordance with the provisions of the Companies Act, 2013 and in compliance with the Secretarial Standards of the Institute of Company Secretaries of India. The details of the Board Meetings, along with the names of the Directors in attendance, are mentioned below:

S. No. Date of the Meeting Number of Directors entitled to attend the Meeting Number of Directors who attended the Meeting
1 07th April 2025 7 7
2 06th May 2025 6 6
3 20th June 2025 10 9
4 25th July 2025 10 9
5 26th August 2025 11 10
6 28th August 2025 11 9
7 16th September 2025 11 11
8 18th September 2025 11 11
9 19th September 2025 11 10
10 23rd September 2025 11 11
11 23rd September 2025 11 11
12 24th September 2025 11 9
13 27th September 2025 11 11
14 29th September 2025 11 9
15 30th September 2025 11 9
16 15th October 2025 11 10
17 24th October 2025 11 11
18 24th November 2025 11 10
19 05th December 2025 11 9

During the financial year 2025-26, five (5) General Meetings were held by the Company. The details of the General Meetings are provided below:

S. No. Date of the Meeting Meeting
1 08th May 2025 Extra-ordinary General Meeting
2 01st August 2025 Extra-ordinary General Meeting
3 28th August 2025 Extra-ordinary General Meeting
4 27th September 2025 Extra-ordinary General Meeting
5 30th September 2025 Annual General Meeting

« O-lineBiotech

16) COMMITTEES OF THE BOARD

In accordance with the applicable provisions of the Companies Act, 2013, the Company has constituted the Audit Committee, Nomination & Remuneration Committee and Stakeholders Relationship Committee. The Corporate Social Responsibility Committee was reconstituted during the financial year 2025-26. The composition of these Committees, along with the details of meetings held during the financial year 2025-26, is provided below:

A. Audit Committee

Pursuant to the provisions of Section 177 of the Companies Act, 2013, the Company has constituted the Audit Committee. The composition of the Committee as at March 31, 2026, and the meetings held during the financial year 2025-26 are as follows:

Name of the Director Status in Committee Nature of Directorship
Pravir Kumar Chairman Independent Director
Jai Prakash Singh Member Independent Director
Ayush Garg Member Non -Executive Director

During the year ended March 31, 2026, two (2) Audit Committee Meetings were held. The maximum time gap between any of the two meetings was not more than 120 days.

S No. Date of The Meeting Committee Strength Number of Directors Present
1 23rd September 2025 3 3
2 05th December 2025 3 3

B. Nomination and Remuneration Committee

Pursuant to the provisions of Section 178 of the Companies Act, 2013, the Company has constituted the Nomination and Remuneration Committee. The composition of the Committee as at March 31, 2026, and the meeting held during the financial year 2025-26 are as follows:

Name of the Director Status in Committee Nature of Directorship
Pravir Kumar Chairman Independent Director
Abhishek Mishra Member Independent Director
Ayush Garg Member Non -Executive Director

The Nomination and Remuneration Committee has met One (1) time during the year under review.

S No. Date of The Meeting Committee Strength Number of Directors Present
1 05th December 2025 3 3

C. Stakeholders Relationship Committee

Pursuant to the provisions of Section 178(5) of the Companies Act, 2013, the Company has constituted the Stakeholders Relationship Committee to consider and resolve the grievances and queries of security holders. The composition of the Committee as at March 31, 2026, is as follows:

Name of the Director Status in Committee Nature of Directorship
Abhishek Mishra Chairman Independent Director
Kuldeep Chowdhry Member Whole Time Director
Yethadka Subraya Prabhakara Member Whole Time Director

During the financial year 2025-26, the Stakeholders Relationship Committee did not meet During the year under review, the Company received Nil complaints from shareholders/ security holders and no complaint was pending for disposal as at March 31, 2026.

17) DEPOSITS:

The Company has not invited/ accepted any deposits from the public during the year ended March 31, 2026. There were no unclaimed or unpaid deposits as on March 31, 2026.

18) CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO:

The information on conservation of energy, technology absorption and foreign exchange earnings and outgo stipulated under Section 134(3)(m) of the Companies Act, 2013 read with Rule, 8 of The Companies (Accounts) Rules, 2014, is annexed herewith as Annexure-I.

19) CORPORATE SOCIAL RESPONSIBILITY:

Pursuant to the requirements of Section 135 of the Companies Act, 2013, the Company has a Corporate Social Responsibility (CSR) Committee. During the financial year under review, the CSR Committee was reconstituted pursuant to changes in its composition. The composition of the CSR Committee as on 31 March 2026 is as follows:

Name of Director Designation in the Committee Nature of Directorship
Rohit Nandan Chairman Independent Director
Yethadka Subraya Prabhakara Member Whole Time Director
Kuldeep Chowdhry Member Whole Time Director

During the financial year 2025-26, the Corporate Social Responsibility Committee met three times.

S No. Date of The Meeting Committee Strength Number of Directors Present
1 25th July 2025 3 3
2 19th September 2025 3 3
3 05th December 2025 3 3

Role of Corporate Social Responsibility Committee:

The role of the Corporate Social Responsibility Committee is as follows:

1. Review the proposals for CSR projects/programs/activities received from various locations;

2. Approve proposals for various CSR projects/programs/activities

3. Identify the projects/activities to be undertaken by the Company for CSR

4. Recommend to the Board CSR Activities to be undertaken along with detailed plan, modalities of execution, implementation schedule, monitoring process and amount to be incurred on such activities

5. Monitor the CSR Policy of the Company from time to time

6. Ensure compliance of CSR Policy and the Rules

7. Such other functions as may be delegated and/or assigned by the Board from time to time

The Corporate Social Responsibility Committee has formulated and recommended to the Board, a Corporate Responsibility Policy (CSR Policy) indicating the activities to be undertaken by the Company, which has been approved by the Board. The key focus areas of the CSR Policy are under;

1. Education: To work on several educational initiatives to provide quality education, training, skill enhancement for improving the quality of living and livelihood. Initiatives are aimed at:

a. Promoting primary and secondary education

b. Imparting Skill development and vocational training

c. Using sports as a tool for development of students in both urban and rural settings

d. Promoting higher education including setting up and supporting skill development centres, Industrial Training Centre.

2. Health: To address issues around affordability and accessibility of quality healthcare and bring about improvement in awareness and health seeking behaviour in various parts of India, enabling a better living, through initiatives such as:

a. Upgrading Primary, secondary and tertiary care facilities

b. Conducting need-based health camps and providing consultation, medicines etc.

c. Working on maternal and child health

d. Improving healthcare delivery through innovative outreach programmes

e. Working in the areas of Communicable and non-communicable diseases

f. Using technology for training, competency evaluation and clinical decision support for medical professionals with a view to improve quality of healthcare.

3- Environment: To enable enhanced livelihood and quality of life, promote environment sustainability through various initiatives for:

a. Ecological sustainability

b. Promoting biodiversity

c. Conservation of natural resources

d. Maintaining quality of soil, air and water

e. Promoting renewable energy

f. Developing gardens and river fronts

4- Other Initiatives: To undertake other need-based initiatives in compliance with Schedule VII of the Companies Act, 2013.

The Company is committed to conducting its business in a socially responsible, ethical, and environmentally friendly manner. It continuously strives to improve the quality of life in the communities within its operational areas. We believe that the sustainable development of our business depends on establishing sustainable, long-lasting, and mutually beneficial relationships with our stakeholders, particularly the communities we engage with.

As responsible corporate citizens, we recognize our role in the integrated and inclusive development of the country, in partnership with the government, corporates, and civil society/ community institutions. Furthermore, we believe that our employees have the potential to contribute not only to our business goals but also to the broader objective of building strong and resilient communities.

The Company is committed to complying with Section 135 of the Companies Act, 2013. Our approach focuses on long-term programmes aligned with community needs. As per the Act, CSR activities may be undertaken directly by the Company or through a registered not-for- profit company, trust, or registered society.

The Annual report on CSR activities is annexed herewith marked as Annexure-II

20) PERFORMANCE AND FINANCIAL POSITION OF EACH OF THE SUBSIDIARIES, ASSOCIATES, JOINT VENTURE INCLUDED IN THE CONSOLIDATED FINANCIAL STATEMENT:

As of 31st March 2026, the Company had one subsidiary and one joint venture.

A detailed report on the performance and financial position of the subsidiary and joint ventures, along with their respective contributions to the Companys overall performance, is presented in Form AOC-1 as Annexure III and forms an integral part of this Report.

21) DIRECTORS RESPONSIBILITY STATEMENT:

Pursuant to the requirement under section 134(3)(C) of the Companies Act, 2013 with respect to Directors Responsibility Statement, it is hereby confirmed that:

a. In the preparation of the annual accounts for the financial year ended 31st March, 2026, the applicable accounting standards had been followed along with proper explanation relating to material departures;

b. The directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company as at March 31, 2026 and of the profit and loss of the company for that period;

c. The directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;

d. The directors have prepared the annual accounts on a going concern basis;

e. That proper Internal Financial Controls were in place and that the Financial Controls were adequate and were operating effectively.

f. The directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

22) ANNUAL EVALUATION OF PERFORMANCE OF THE BOARD, ITS COMMITTEES AND INDIVIDUAL DIRECTORS

Pursuant to the provisions of Section 134(3)(p) of the Companies Act, 2013 read with the applicable rules made thereunder, the Board of Directors has carried out an annual evaluation of its own performance, the performance of its Committees and that of individual Directors.

The evaluation was carried out based on various parameters, including the composition and effectiveness of the Board and its Committees, participation and contribution of Directors in the meetings, quality and timeliness of information provided to the Board, strategic guidance, oversight of financial reporting and internal controls, adherence to applicable laws and regulations, and the overall effectiveness of the Board and its Committees.

The Board is of the opinion that the Board as a whole, its Committees and the individual Directors have performed satisfactorily and effectively during the financial year 2025-26. The evaluation process has further contributed to identifying areas for continued improvement in the functioning of the Board and its Committees.

The Board is also of the opinion that the Independent Directors appointed possess the requisite integrity, expertise, experience and proficiency required for the effective discharge of their duties and responsibilities.

23) PREVENTION OF SEXUAL HARASSMENT OF WOMEN AT WORKPLACE:

The Company is committed to providing a safe, secure and respectful working environment and has adopted a policy on prevention, prohibition and redressal of sexual harassment at the workplace in accordance with the provisions of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 (POSH Act).

4

4

In compliance with the applicable provisions of the POSH Act, the Company has constituted an Internal Complaints Committee (ICC) to receive and redress complaints relating to sexual harassment at the workplace.

The details pertaining to complaints under the provisions of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 are as below:

S. No. Particulars
1 Number of complaints of sexual harassment received in the year - Nil
2 Number of complaints disposed off during the year - Nil
3 Number of cases pending for more than ninety days - Nil

24) MATERNITY BENEFIT PROVIDED BY THE COMPANY UNDER MATERNITY BENEFIT ACT 1961

The Company declares that it has duly complied with the provisions of the Maternity Benefit Act, 1961. All eligible women employees have been extended the statutory benefits prescribed under the Act, including paid maternity leave, continuity of salary and service during the leave period, and post-maternity support such as nursing breaks and flexible return-to-work options, as applicable. The Company remains committed to fostering an inclusive and supportive work environment that upholds the rights and welfare of its women employees in accordance with applicable laws.

25) DECLARATION BY INDEPENDENT DIRECTORS:

The Company has received necessary declarations from all Independent Directors of the Company in accordance with the provisions of Section 149(7) of the Companies Act, 2013 confirming that they meet the criteria of independence as prescribed under Section 149(6) of the Companies Act, 2013.

The Board is of the opinion that the Independent Directors possess the requisite integrity, expertise and experience. None of the Independent Directors is liable to retire by rotation in accordance with the provisions of the Companies Act, 2013.

26) COMPANYS POLICY ON DIRECTORS APPOINTMENT AND REMUNERATION INCLUDING CRITERIA FOR DETERMINING QUALIFICATIONS, POSITIVE ATTRIBUTES, INDEPENDENCE OF A DIRECTOR AND OTHER MATTERS PROVIDED UNDER SUB-SECTION (3) OF SECTION 178:

The Companys Remuneration Policy is aimed at rewarding performance based on periodic review of achievements and is in line with the prevailing industry practices. The Company has constituted the Nomination and Remuneration Committee (NRC) The NRC is responsible for recommending to the Board the appointment and remuneration of Directors and for determining the criteria relating to their qualifications, positive attributes and independence, in accordance with Section 178 of the Companies Act, 2013.

The Companys Shareholders may refer the Companys website for the Remuneration Policy of the Company on the appointment and remuneration of Directors including criteria for determining qualifications, positive attributes, independence of a Director; and other matters provided under Sub-Section (3) of Section 178.

27) CREDIT RATING ON CREDIT FACILITIES FROM BANK:

The Companys financial discipline, prudent financial management and strong credit profile are reflected in the credit ratings assigned to its bank facilities.

Subsequent to the closure of the financial year 2025-26 and prior to the date of signing of this Boards Report, the Company changed its credit rating agency from CRISIL Ratings Limited to CARE Ratings Limited for rating of its bank facilities.

Pursuant to the aforesaid change, CARE Ratings Limited, vide its rating communication dated August 21, 2026, assigned a long-term rating of CARE A- with a Stable outlook to

the Companys long-term bank facilities. Further, the Companys long-term/short-term bank facilities have been assigned a rating of CARE A-; Stable / CARE A2+, while its short-term bank facilities have been assigned CARE A2+.

The rating assigned by CARE Ratings Limited marks a significant improvement in the Companys credit profile, with the long-term rating moving from the earlier CRISIL BBB+ with a Stable outlook to CARE A- with a Stable outlook, thereby placing the Company in the A rating category. The enhanced rating is a positive reflection of the Companys financial strength, creditworthiness and prudent financial management.

The improved credit rating further reinforces the confidence of financial institutions and other stakeholders in the Companys ability to meet its financial obligations in a timely manner and reflects the Companys continued focus on maintaining sound financial discipline and strengthening its overall credit profile.

As per the rating communication issued by CARE Ratings Limited, the ratings cover aggregate bank facilities of 221.30 crore, comprising long-term facilities of 20.00 crore, short-term facilities of 16.00 crore and long-term/short-term facilities of 185.30 crore.

28) PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS UNDER SECTION 186:

During the year under review, the Company has complied with the provisions of Section 186 of the Companies Act, 2013, related to loans, guarantees, and investments.

During the year, the Company provided a corporate guarantee in favour of Q-Line Innovations Pvt. Ltd. for an amount not exceeding 7 crore, for facilitating the availment of loan facilities from OXYZO Financial Services Limited, pursuant to the approval of the members by way of Special Resolution passed on 28 August 2025.

The Company has investments in the shares of other body corporates and is in compliance with the provisions of Section 186. The details of these investments are as follows (refer to Note No. 13 of the Financial Statements for further details):

S. No. Name of the Company Number of Shares
1 Q-Line Innovations Pvt. Ltd. 7,000
2 Q-Line Iris Pvt. Ltd. 5,000
3 POCT Science House Private Limited 100

29) RELATED PARTY TRANSACTIONS:

During the year under review, the Company entered into transactions with related parties in the ordinary course of business and on an arms length basis, wherever applicable. The particulars of contracts or arrangements with related parties referred to in Section 188(1) of the Companies Act, 2013 are provided in Form AOC-2, annexed to this Report as Annexure IV.

30) DISCLOSURES RELATED TO POLICIES

I. Appointment of Independent Directors

The Company has adopted a Nomination Policy to identify persons who are qualified to become Independent Directors on the Board of the Company and recommend their appointment who have the capacity and ability to lead the Company towards achieving sustainable development. The Nomination Policy of the Company is available on website of the Company.

II. Code of Conduct for Board and Senior Management Personnel

The Company has adopted a Code of Conduct for the Board of Directors and Senior Management Personnel, which lays down the principles of ethical business conduct, integrity, transparency, accountability and compliance with applicable laws and regulations. The Code serves as a guiding framework for maintaining the highest standards of professional and ethical behaviour in the conduct of the Companys affairs. All Directors and Senior Management Personnel have affirmed their compliance with the Code of Conduct for the Financial Year ended March 31, 2026. The Code of Conduct is available on the website of the Company.

III. Whistle Blower Policy and Vigil Mechanism

The Board has, pursuant to the provisions of Section 177(9) of the Companies Act, 2013 read with Rule 7 of the Companies (Meetings of Board and its Powers) Rules, 2014, framed Whistle Blower Policy and Vigil Mechanism. The vigil mechanism of your Company provides for adequate safeguards against victimization of whistle blowers who avail of the mechanism and provides for direct access to the Chairman of the Audit Committee. No person has been denied access to the Chairman of the Audit Committee. The said policy is available on the website of the Company.

IV. Material Subsidiary Policy

The Company has adopted a Policy for Determination of Material Subsidiaries with reference to the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Policy is available on the Companys website.

The applicability of the corporate governance provisions of the SEBI Listing Regulations to the Company is subject to the provisions applicable to entities listed on the SME Exchange.

31) DISCLOSURES RELATING TO REMUNERATION AS PER THE COMPANIES (APPOINTMENT AND REMUNERATION OF MANAGERIAL PERSONNEL) RULES, 2014:

The disclosures relating to remuneration of Directors and Key Managerial Personnel as required under Section 197(12) of the Companies Act, 2013 read with Rule 5 of the Companies

(Appointment and Remuneration of Managerial Personnel) Rules, 2014 are provided in Annexure-V forming part of this Report.

32) DISCLOSURE WHETHER MAINTENANCE OF COST RECORDS AS SPECIFIED BY CENTRAL GOVERNMENT UNDER SUB SECTION 1 OF SECTION 148 OF COMPANIES ACT 2013 IS REQUIRED BY THE COMPANY AND ACCORDINGLY SUCH RECORDS AND ACCOUNTS ARE MAINTAINED BY THE COMPANY: -

Pursuant to the provisions of Section 148(1) of the Companies Act, 2013 (Act) read with the Companies (Cost Records and Audit) Rules, 2014, the Company is required to maintain cost records in respect of the applicable products/activities of the Company. Accordingly, the prescribed cost records and accounts are duly maintained by the Company.

Further, pursuant to Section 148 of the Act read with the Companies (Cost Records and Audit) Rules, 2014, the Board of Directors, on the recommendation of the Audit Committee, has appointed M/s P S P & Associates, Cost Accountants (Firm Registration No. 005591), as the Cost Auditor of the Company to conduct the audit of the cost records of the Company for the financial year ending March 31, 2027, in respect of the products/activities for which cost audit is applicable.

M/s P S P & Associates have furnished their consent to act as Cost Auditor and a certificate confirming their eligibility for appointment in accordance with the applicable provisions of the Act and the rules made thereunder.

The Board of Directors, on the recommendation of the Audit Committee, has also approved the remuneration payable to the Cost Auditor for the financial year ending March 31, 2027, subject to ratification by the Members of the Company. Accordingly, a resolution for ratification of the remuneration payable to the Cost Auditor forms part of the Notice convening the ensuing Annual General Meeting.

33) SECRETARIAL AUDITORS

Pursuant to the provisions of Section 204 of the Companies Act, 2013 read with Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 as amended from time to time , the Board of Directors have appointed M/s. MMA & Partners (Firm Registration Number: P2015UP081000), Practicing Company Secretary, as the Secretarial Auditor of the Company for the Financial Year 2025-2026.

The Secretarial Auditor, has issued the Secretarial Audit Report in Form MR-3 for the Financial Year 2025-2026, pursuant to the provisions of Section 204 of the Companies Act, 2013, which is annexed herewith as Annexure -VII

During the year under review, there were no qualifications, reservations or adverse remarks reported by Secretarial Auditor under Section 204 of the Companies Act, 2013 in the course of the performance of his duties as Secretarial Auditor.

34) BUSINESS RISK MANAGEMENT:

The Company has appropriate systems and processes in place for identifying, assessing and managing risks associated with its business. The Board periodically reviews the key risks and takes appropriate measures for their mitigation.

During the year under review, no risk has been identified which, in the opinion of the Board, may threaten the existence of the Company.

35) COMPLIANCE WITH SECRETARIAL STANDARDS:

The applicable Secretarial Standards, i.e., SS-1 and SS-2 relating to Meetings of the Board of Directors and General Meetings, respectively, had been duly complied by the Company.

36) DETAILS OF DIFFERENCE BETWEEN AMOUNT OF THE VALUATION DONE AT THE TIME OF ONE-TIME SETTLEMENT AND THE VALUATION DONE WHILE TAKING LOAN FROM THE BANKS OR FINANCIAL INSTITUTIONS.

During the year under review, there was no instance of any one-time settlement for reporting details vis-a-vis valuation with the Banks or Financial Institutions.

37) PROCEEDINGS PENDING UNDER THE INSOLVENCY AND BANKRUPTCY CODE

During the Financial Year under review, no application was made, nor was any proceeding pending, against the Company under the provisions of the Insolvency and Bankruptcy Code, 2016 (31 of 2016). Accordingly, there was no proceeding initiated or pending under the Insolvency and Bankruptcy Code, 2016 as at March 31, 2026.

38) DIVIDEND AND INVESTOR EDUCATION AND PROTECTION FUND (IEPF)

The Board has not recommended/declared any dividend for FY 2025-26. Accordingly, no amount was required to be transferred to the Investor Education and Protection Fund during the financial year.

39) CHANGE IN AUTHORISED SHARE CAPITAL

I. Authorized Share Capital

As on March 31, 2026, the Authorized Share capital of the Company was 25,00,00,000 (Rupees Twenty- Five Crores only) comprising 2,50,00,000 (Two Crores Fifty Lakhs) Equity shares of face value of 10/- each.

During the year under review, the Company has increased its Authorized Share Capital from Rs. 4,00,00,000/- (Rupees Four Crores Only) divided into 40,00,000/- (Forty Lakhs) Equity Shares of Rs. 10/- each to Rs. 25,00,00,000/- (Twenty-Five Crores only) divided into

2.50.00. 000/- (Two Crores Fifty Lakhs Only) equity shares of Rs. 10/- each by increasing of

2.10.00. 000 ( Two Crores Ten Lakhs only) equity shares of face value Rs. 10/- each.

II. Paid Up Share Capital

As on March 31, 2026, the Paid-up share capital of the Company was 16,27,49,990/- (Rupees Sixteen Crores Twenty-Seven lakhs and Forty Nine Thousand Nine Hundred Ninety Only) comprising 1,62,74,999/- (One Crore Sixty-Two Lakhs and Seventy Four Thousand Nine Hundred Ninety Nine) Equity shares of face value of 10/- (Ten) each.

During the year under review, the Company made the following allotments of Equity Shares

1. Company has made a Right issue of 5,24,999 (Five Lakhs Twenty-Four Thousand and Nine Hundred Ninety-Nine) Equity Shares of face value of 10/- (Ten).

2. Company has made a Bonus Issue of 1,41,75,000 (One Crore Forty-One Lakh Seventy-Five Thousand) Equity Shares of face value of 10/- (Rupees Ten only) each, by way of Bonus Shares, to the existing shareholders of the Company in accordance with the applicable provisions of the Companies Act, 2013.

IN. Issue of Equity Shares with Differential Rights

The Company has not issued any Equity Shares with Differential Voting Rights during the Financial Year ended March 31, 2026.

IV. Issue of Sweat Equity Shares

The Company has not issued any Sweat Equity Shares during the Financial Year ended March 31, 2026.

V. Employee Stock Option Scheme (ESOP)

The Company has not granted any Employee Stock Options during the Financial Year ended March 31, 2026.

VI. Provision of Money for Purchase of Own Shares

The Company has not made any provision for purchase of its own shares by employees or by trustees for the benefit of employees during the Financial Year under review.

40) ACKNOWLEDGMENT:

Your Directors take this opportunity to place on record their appreciation and sincere gratitude to the Members of the Company, Bankers and other Financial Institutions, Government of India, State Government, Local Bodies, Customers & Suppliers, of the Company for their valuable support and look forward to their continued co-operation in the years to come.

Your Directors acknowledge the support and co-operation received from the employees at all levels and consultants for their continuous co-operation and assistance in management and day to day operation of the Company.

FOR & ON BEHALF OF THE BOARD OF DIRECTORS OF Q-LINE BIOTECH LIMITED

(FORMERLY KNOWN AS Q-LINE BIOTECH PRIVATE LIMITED)

Date : 05.09.2026 (Saurabh Garg) (Amita Garg)
Place : Lucknow Managing Director & Chairman Director
DIN:02891621 DIN:02891610

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2026, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited. All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099

ISO certification icon
We are ISO/IEC 27001:2022 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.